Lyell Immunopharma, Inc., a clinical-stage company focused on advancing CAR T-cell therapies for cancer treatment, will participate in the H.C. Wainwright "HCW@Home" Series on June 25, 2025. During the event, Lyell's senior management, including President and CEO Lynn Seely and CFO Charlie Newton, will discuss positive new clinical data on LYL314, a dual-targeting CAR T-cell product candidate for large B-cell lymphoma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.